Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study

Dow Jones04-22 05:28

By Christopher Kuo

Inhibrx Biosciences provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer.

The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment.

The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells.

The company also said 42% of the trial's patients remained progression-free at the 6-month landmark.

The overall disease control rate was 87%, the company said.

The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma.

The FDA previously granted Fast Track designation to ozekibart in 2021.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 21, 2026 17:28 ET (21:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629658640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629658640","market":"sg","top_or_hot":-1,"title":"Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer. \n</p>\n<p>\n  The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment. \n</p>\n<p>\n  The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells. \n</p>\n<p>\n  The company also said 42% of the trial's patients remained progression-free at the 6-month landmark. \n</p>\n<p>\n  The overall disease control rate was 87%, the company said. \n</p>\n<p>\n  The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma. \n</p>\n<p>\n  The FDA previously granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation to ozekibart in 2021. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences Gives Updated Data From Cancer Treatment Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-22 05:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer. \n</p>\n<p>\n  The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment. \n</p>\n<p>\n  The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells. \n</p>\n<p>\n  The company also said 42% of the trial's patients remained progression-free at the 6-month landmark. \n</p>\n<p>\n  The overall disease control rate was 87%, the company said. \n</p>\n<p>\n  The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma. \n</p>\n<p>\n  The FDA previously granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation to ozekibart in 2021. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629658640","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629658640","pubTimestamp":1776806880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inhibrx Biosciences provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer.The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment.The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells.The company also said 42% of the trial's patients remained progression-free at the 6-month landmark.The overall disease control rate was 87%, the company said.The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma.The F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"Inhibrx Biosciences提供癌症治疗研究的最新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\nInhibrx Biosciences provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer. \n\n\n  The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment. \n\n\n  The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells. \n\n\n  The company also said 42% of the trial's patients remained progression-free at the 6-month landmark. \n\n\n  The overall disease control rate was 87%, the company said. \n\n\n  The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma. \n\n\n  The FDA previously granted Fast Track designation to ozekibart in 2021. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2026 17:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629658640","isCrawlerRequest":true}